Lille (France), Boston (Massachusetts, United States), March 13, 2013 – GENFIT (Alternext: ALGFT; ISIN:
FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, today
announces that it has discovered and validated a series of novel and proprietary ligands for the treatment of
These compounds inhibit the secretion of interleukin IL-17 from the stimulated Th17 lymphocytes, by
antagonizing the activity of the nuclear receptor ROR?t. These results represent a significant step forward in
future development of new drug candidates for the treatment of diseases that express the Th17 component.
Indeed, the IL-17 pathway is today recognized as a major pathological player in the etiology of several auto-
immune diseases such as Psoriasis, Multiple Sclerosis, Rheumatoid Arthritis and Inflammatory Bowel Disease.
In addition, both clinical and preclinical data accumulate to demonstrate that the same Th17 pathway is
present and important for development of other inflammatory and cardiometabolic diseases.
Dr. Robert Walczak, the Director of Pharmacology at GENFIT, declared: “The conception of synthetic, orally
available small molecule ligands that interfere with the production and with systemic pathological actions of
the family of IL-17 cytokines is an important achievement for drug discovery at GENFIT. Major pharmaceutical
companies have invested considerable budgets to develop biologic agents that target the IL17-IL17R pathway.
Some of these treatments have recently demonstrated exceptional therapeutic properties in patients with
psoriasis but clearly this area is in its infancy and sufficient space remains to bring analogous treatments. Our
approach to target this important pathogenic pathway with small synthetic molecules will bring more flexibility
in terms of possible routes of administration (i.e. oral, topical, inhaled) and also considerably lower costs of
manufacturing, which will finally translate into more affordable treatment regimens.”
Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, concluded: “We are delighted that
our efforts to conceive functional ROR?t ligands have come to fruition. The results obtained with our proprietary
molecules acting on this receptor enable us to strengthen our pipeline, and clearly show that an ambitious
optimization program can now be undertaken. This field is a particularly hot subject in the strategy of major
pharmaceutical companies, as judged from the recent deals. At this stage, we are very pleased with the interest
generated by GENFIT’s results and with the discussions that are currently in progress with potential partners.”
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in
therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia,
inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive
solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in
partnership with leading pharmaceutical companies, including Sanofi, to address these major public health
concerns and their unmet medical needs.
Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in
these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English languages. In the
event of any differences between the two texts, the French language version shall supersede.
GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates
at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees.
GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN:
Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000
MILESTONES – Press Relations
Ph. +331 7544 8740 / +336 8788 4726 – email@example.com